May 30 (Reuters) - Merck & Co Inc MRK.N:
MERCK ANNOUNCES MK-1084, AN INVESTIGATIONAL KRAS G12C INHIBITOR, SHOWS ANTITUMOR ACTIVITY IN PHASE 1 TRIAL OF PATIENTS WITH ADVANCED COLORECTAL CANCER AND NON-SMALL CELL LUNG CANCER WHOSE TUMORS HARBOR KRAS G12C MUTATIONS
MERCK & CO INC - MK-1084 TO BE INVESTIGATED IN PHASE 3 KANDLELIT-012 AND KANDLELIT-004 STUDIES
MERCK & CO INC - MK-1084 SHOWS MANAGEABLE SAFETY PROFILE AND ANTITUMOR ACTIVITY
Source text: ID:nBw6DLvYHa
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.